This agrees with current clinical practice which uses mTOR and BRAF inhibitors as first-line therapy for kidney cancer and melanoma, respectively [63, 64], since the c-Met/mTOR axis is frequently altered in kidney cancer [65, 66] while BRAF mutations are the main genetic drivers of melanoma [64]. The gene discussed is MET; the disease is melanoma.